131 related articles for article (PubMed ID: 37914019)
1. Setd2 deficiency promotes gastric tumorigenesis through inhibiting the SIRT1/FOXO pathway.
Feng W; Ma C; Rao H; Zhang W; Liu C; Xu Y; Aji R; Wang Z; Xu J; Gao WQ; Li L
Cancer Lett; 2023 Nov; 579():216470. PubMed ID: 37914019
[TBL] [Abstract][Full Text] [Related]
2. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.
Niu N; Lu P; Yang Y; He R; Zhang L; Shi J; Wu J; Yang M; Zhang ZG; Wang LW; Gao WQ; Habtezion A; Xiao GG; Sun Y; Li L; Xue J
Gut; 2020 Apr; 69(4):715-726. PubMed ID: 31300513
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.
Yuan H; Li N; Fu D; Ren J; Hui J; Peng J; Liu Y; Qiu T; Jiang M; Pan Q; Han Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Sep; 127(9):3375-3391. PubMed ID: 28825595
[TBL] [Abstract][Full Text] [Related]
4. SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis.
Xie Y; Sahin M; Wakamatsu T; Inoue-Yamauchi A; Zhao W; Han S; Nargund AM; Yang S; Lyu Y; Hsieh JJ; Leslie CS; Cheng EH
JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36810256
[TBL] [Abstract][Full Text] [Related]
5. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
[TBL] [Abstract][Full Text] [Related]
6. The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis.
Liu M; Rao H; Liu J; Li X; Feng W; Gui L; Tang H; Xu J; Gao WQ; Li L
Redox Biol; 2021 Jul; 43():102004. PubMed ID: 34020310
[TBL] [Abstract][Full Text] [Related]
7. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.
Zhang YL; Sun JW; Xie YY; Zhou Y; Liu P; Song JC; Xu CH; Wang L; Liu D; Xu AN; Chen Z; Chen SJ; Sun XJ; Huang QH
Cell Res; 2018 Apr; 28(4):476-490. PubMed ID: 29531312
[TBL] [Abstract][Full Text] [Related]
8. SETD2 indicates favourable prognosis in gastric cancer and suppresses cancer cell proliferation, migration, and invasion.
Chen Z; Raghoonundun C; Chen W; Zhang Y; Tang W; Fan X; Shi X
Biochem Biophys Res Commun; 2018 Apr; 498(3):579-585. PubMed ID: 29522714
[TBL] [Abstract][Full Text] [Related]
9. Tumor Cell-Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis.
Niu N; Shen X; Zhang L; Chen Y; Lu P; Yang W; Liu M; Shi J; Xu D; Tang Y; Yang X; Weng Y; Zhao X; Wu LM; Sun Y; Xue J
Adv Sci (Weinh); 2023 Jan; 10(2):e2202937. PubMed ID: 36453584
[TBL] [Abstract][Full Text] [Related]
10. SETD2-dependent H3K36me3 plays a critical role in epigenetic regulation of the HPV31 life cycle.
Gautam D; Johnson BA; Mac M; Moody CA
PLoS Pathog; 2018 Oct; 14(10):e1007367. PubMed ID: 30312361
[TBL] [Abstract][Full Text] [Related]
11. Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1-IL-8 signaling-mediated epithelial-mesenchymal transition in lung adenocarcinoma.
Yang X; Chen R; Chen Y; Zhou Y; Wu C; Li Q; Wu J; Hu WW; Zhao WQ; Wei W; Shi JT; Ji M
Cancer Sci; 2022 Apr; 113(4):1195-1207. PubMed ID: 35152527
[TBL] [Abstract][Full Text] [Related]
12. The SETD2 Methyltransferase Supports Productive HPV31 Replication through the LEDGF/CtIP/Rad51 Pathway.
Mac M; DeVico BM; Raspanti SM; Moody CA
J Virol; 2023 May; 97(5):e0020123. PubMed ID: 37154769
[TBL] [Abstract][Full Text] [Related]
13. SETD2 epidermal deficiency promotes cutaneous wound healing via activation of AKT/mTOR Signalling.
Li X; Liu C; Zhu Y; Rao H; Liu M; Gui L; Feng W; Tang H; Xu J; Gao WQ; Li L
Cell Prolif; 2021 Jun; 54(6):e13045. PubMed ID: 33949020
[TBL] [Abstract][Full Text] [Related]
14. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
15. miR-543 promotes gastric cancer cell proliferation by targeting SIRT1.
Li J; Dong G; Wang B; Gao W; Yang Q
Biochem Biophys Res Commun; 2016 Jan; 469(1):15-21. PubMed ID: 26612257
[TBL] [Abstract][Full Text] [Related]
16. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation.
Javaid H; Barberis A; Chervova O; Nassiri I; Voloshin V; Sato Y; Ogawa S; Fairfax B; Buffa F; Humphrey TC
BMC Cancer; 2023 Aug; 23(1):721. PubMed ID: 37528416
[TBL] [Abstract][Full Text] [Related]
17. SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS.
Chen BY; Song J; Hu CL; Chen SB; Zhang Q; Xu CH; Wu JC; Hou D; Sun M; Zhang YL; Liu N; Yu PC; Liu P; Zong LJ; Zhang JY; Dai RF; Lan F; Huang QH; Zhang SJ; Nimer SD; Chen Z; Chen SJ; Sun XJ; Wang L
Blood; 2020 Jun; 135(25):2271-2285. PubMed ID: 32202636
[TBL] [Abstract][Full Text] [Related]
18. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
19. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
20. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
Kumari S; Muthusamy S
Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
